Steven Cohen Bio Atla, Inc. Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.3 - $8.25 $1.49 Million - $5.36 Million	-649,680 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$6.29 - $11.01 $723,475 - $1.27 Million	-115,020 Reduced 15.04%	649,680 $5.36 Million
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $2.25 Million - $9.08 Million	764,700 New	764,700 $5.89 Million
Q4 2021 Feb 14, 2022	SELL	$19.0 - $30.95 $2.44 Million - $3.98 Million	-128,622 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $3.79 Million - $5.63 Million	128,622 New	128,622 $3.79 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.